SEARCH

SEARCH BY CITATION

References

  • Abdel-Wahab, O., Mullally, A., Hedvat, C., Garcia-Manero, G., Patel, J., Wadleigh, M., Malinge, S., Yao, J., Kilpivaara, O., Bhat, R., Huberman, K., Thomas, S., Dolgalev, I., Heguy, A., Paietta, E., Le Beau, M.M., Beran, M., Tallman, M.S., Ebert, B.L., Kantarjian, H.M., Stone, R.M., Gilliland, D.G., Crispino, J.D. & Levine, R.L. (2009) Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood, 114, 144147.
  • Advani, A.S., Gibson, S.E., Douglas, E., Jin, T., Zhao, X., Kalaycio, M., Copelan, E., Sobecks, R., Sekeres, M., Sungren, S. & Hsi, E.D. (2010) Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients. BMC Cancer, 10, 387.
  • Amin, S., Walsh, M., Wilson, C., Parker, A.E., Oscier, D., Willmore, E., Mann, D. & Mann, J. (2011) Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL. Journal of Cellular and Molecular Medicine, Doi: 10.1111/j.1582-4934.2011.01503.x [Epub ahead of print].
  • Badros, A., Burger, A.M., Philip, S., Niesvizky, R., Kolla, S.S., Goloubeva, O., Harris, C., Zwiebel, J., Wright, J.J., Espinoza-Delgado, I., Baer, M.R., Holleran, J.L., Egorin, M.J. & Grant, S. (2009) Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clinical Cancer Research, 15, 52505257.
  • Bannister, A.J. & Kouzarides, T. (2011) Regulation of chromatin by histone modifications. Cell Research, 21, 381395.
  • Beaulieu, N., Morin, S., Chute, I.C., Robert, M.F., Nguyen, H. & MacLeod, A.R. (2002) An essential role for DNA methyltransferase DNMT3B in cancer cell survival. Journal of Biological Chemistry, 277, 2817628181.
  • Bell, C.G. & Beck, S. (2010) The epigenomic interface between genome and environment in common complex diseases. Briefings in Functional Genomics, 9, 477485.
  • Benedikt, A., Baltruschat, S., Scholz, B., Bursen, A., Arrey, T.N., Meyer, B., Varagnolo, L., Müller, A.M., Karas, M., Dingermann, T. & Marschalek, R. (2011) The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia, 25, 135144.
  • Birke, M., Schreiner, S., García-Cuéllar, M.P., Mahr, K., Titgemeyer, F. & Slany, R.K. (2002) The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nuclic Acids Research, 30, 958965.
  • Bitoun, E., Oliver, P.L. & Davies, K.E. (2007) The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Human Molecular Genetics, 16, 92106.
  • Blum, W., Klisovic, R.B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., Plass, C., Devine, S.M., Heerema, N.A., Murgo, A., Chan, K.K., Grever, M.R., Byrd, J.C. & Marcucci, G. (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Journal of Clinical Oncology, 25, 38843891.
  • Blum, K.A., Liu, Z., Lucas, D.M., Chen, P., Xie, Z., Baiocchi, R., Benson, D.M., Devine, S.M., Jones, J., Andritsos, L., Flynn, J., Plass, C., Marcucci, G., Chan, K.K., Grever, M.R. & Byrd, J.C. (2010) Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. British Journal of Haematology, 150, 189195.
  • Bohannon, R.A., Miller, D.G. & Diamond, H.D. (1963) Vincristine in the treatment of lymphomas and leukemias. Cancer Research, 23, 613621.
  • Boultwood, J. & Wainscoat, J.S. (2007) Gene silencing by DNA methylation in haematological malignancies. British Journal of Haematology, 138, 311.
  • Bracken, A.P., Dietrich, N., Pasini, D., Hansen, K.H. & Helin, K. (2006) Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes & Development, 20, 11231136.
  • Bradford, P.T., Devesa, S.S., Anderson, W.F. & Toro, J.R. (2009) Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood, 113, 50645073.
  • Brodska, B., Otevrelova, P. & Holoubek, A. (2011) Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA. Molecular and Cellular Biochemistry, 350, 7180.
  • Broeker, P.L., Harden, A., Rowley, J.D. & Zeleznik-Le, N. (1996) The mixed lineage leukemia (MLL) protein involved in 11q23 translocations contains a domain that binds cruciform DNA and scaffold attachment region (SAR) DNA. Current Topics in Microbiology and Immunology, 211, 259268.
  • Burchenal, J.H., Murphy, M.L., Ellison, R.R., Sykes, M.P., Tan, T.C., Leone, L.A., Karnofsky, D.A., Craver, L.F., Dargeon, H.W. & Rhoads, C.P. (1953) Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood, 8, 965999.
  • Bursen, A., Moritz, S., Gaussmann, A., Moritz, S., Dingermann, T. & Marschalek, R. (2004) Interaction of AF4 wild-type and AF4•MLL fusion protein with SIAH proteins: indication for t(4;11) pathobiology? Oncogene, 23, 62376249.
  • Bursen, A., Schwabe, K., Rüster, B., Henschler, R., Ruthardt, M., Dingermann, T. & Marschalek, R. (2010) The AF4-MLL fusion protein is capable of inducing ALL in mice without requirement of MLL-AF4. Blood, 115, 35703579.
  • Campbell, P.J., Yachida, S., Mudie, L.J., Stephens, P.J., Pleasance, E.D., Stebbings, L.A., Morsberger, L.A., Latimer, C., McLaren, S., Lin, M.L., McBride, D.J., Varela, I., Nik-Zainal, S.A., Leroy, C., Jia, M., Menzies, A., Butler, A.P., Teague, J.W., Griffin, C.A., Burton, J., Swerdlow, H., Quail, M.A., Stratton, M.R., Iacobuzio-Donahue, C. & Futreal, P.A. (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 467, 11091113.
  • Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., Xi, Y., Liang, S., Lu, Y., Darlington, G.J., Meissner, A., Issa, J.P., Godley, L.A., Li, W. & Goodell, M.A. (2011) Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genetics, 44, 2331.
  • Chang, P.Y., Hom, R.A., Musselman, C.A., Zhu, L., Kuo, A., Gozani, O., Kutateladze, T.G. & Cleary, M.L. (2010a) Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription. Journal of Molecular Biology, 400, 137144.
  • Chang, M.J., Wu, H., Achille, N.J., Reisenauer, M.R., Chou, C.W., Zeleznik-Le, N.J., Hemenway, C.S. & Zhang, W. (2010b) Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Research, 70, 1023410242.
  • Chen, S.S., Claus, R., Lucas, D.M., Yu, L., Qian, J., Ruppert, A.S., West, D.A., Williams, K.E., Johnson, A.J., Sablitzky, F., Plass, C. & Byrd, J.C. (2011) Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood, 117, 862871.
  • Choudhary, C., Kumar, C., Gnad, F., Nielsen, M.L., Rehman, M., Walther, T.C., Olsen, J.V. & Mann, M. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 325, 834840.
  • Chowdhury, R., Yeoh, K.K., Tian, Y.M., Hillringhaus, L., Bagg, E.A., Rose, N.R., Leung, I.K., Li, X.S., Woon, E.C., Yang, M., McDonough, M.A., King, O.N., Clifton, I.J., Klose, R.J., Claridge, T.D., Ratcliffe, P.J., Schofield, C.J. & Kawamura, A. (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Reports, 12, 463469.
  • Chuang, J.C., Warner, S.L., Vollmer, D., Vankayalapati, H., Redkar, S., Bearss, D.J., Qiu, X., Yoo, C.B. & Jones, P.A. (2010) S110, a 5-Aza-2′-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Molecular Cancer Therapeutics, 9, 14431450.
  • Daigle, S.R., Olhava, E.J., Therkelsen, C.A., Majer, C.R., Sneeringer, C.J., Song, J., Johnston, L.D., Scott, M.P., Smith, J.J., Xiao, Y., Jin, L., Kuntz, K.W., Chesworth, R., Moyer, M.P., Bernt, K.M., Tseng, J.C., Kung, A.L., Armstrong, S.A., Copeland, R.A., Richon, V.M. & Pollock, R.M. (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell, 20, 5365.
  • Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., Marks, K.M., Prins, R.M., Ward, P.S., Yen, K.E., Liau, L.M., Rabinowitz, J.D., Cantley, L.C., Thompson, C.B., Vander Heiden, M.G. & Su, S.M. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462, 739744.
  • Datta, J., Ghoshal, K., Denny, W.A., Gamage, S.A., Brooke, D.G., Phiasivongsa, P., Redkar, S. & Jacob, S.T. (2009) A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Research, 69, 42774285.
  • Dawson, M.A., Prinjha, R.K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.I., Robson, S.C., Chung, C.W., Hopf, C., Savitski, M.M., Huthmacher, C., Gudgin, E., Lugo, D., Beinke, S., Chapman, T.D., Roberts, E.J., Soden, P.E., Auger, K.R., Mirguet, O., Doehner, K., Delwel, R., Burnett, A.K., Jeffrey, P., Drewes, G., Lee, K., Huntly, B.J. & Kouzarides, T. (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature, 478, 529533.
  • Defoiche, J., Debacq, C., Asquith, B., Zhang, Y., Burny, A., Bron, D., Lagneaux, L., Macallan, D. & Willems, L. (2008) Reduction of B cell turnover in chronic lymphocytic leukaemia. British Journal of Haematology, 143, 240247.
  • Defossez, P.A. & Stancheva, I. (2011) Biological functions of methyl-CpG-binding proteins. Progress in Molecular Biology and Translational Science, 101, 377398.
  • Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.P., Robert, F., Alberdi, A., Lécluse, Y., Plo, I., Dreyfus, F.J., Marzac, C., Casadevall, N., Lacombe, C., Romana, S.P., Dessen, P., Soulier, J., Viguié, F., Fontenay, M., Vainchenker, W. & Bernard, O.A. (2009) Mutation in TET2 in myeloid cancers. The New England Journal of Medicine, 360, 22892301.
  • Dimicoli, S., Jabbour, E., Borthakur, G., Kadia, T., Estrov, Z., Yang, H., Kelly, M., Pierce, S., Kantarjian, H. & Garcia-Manero, G. (2012) Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. American Journal of Hematology, 87, 127129.
  • Dou, Y., Milne, T.A., Tackett, A.J., Smith, E.R., Fukuda, A., Wysocka, J., Allis, C.D., Chait, B.T., Hess, J.L. & Roeder, R.G. (2005) Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell, 121, 873885.
  • Dou, Y., Milne, T.A., Ruthenburg, A.J., Lee, S., Lee, J.W., Verdine, G.L., Allis, C.D. & Roeder, R.G. (2006) Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nature Structural and Molecular Biology, 13, 713719.
  • Engel, N. & Rank, A. (2011) Epigenomics in hematopoietic transplantation: novel treatment strategies. Epigenomics, 3, 611623.
  • Ernst, P., Wang, J., Huang, M., Goodman, R.H. & Korsmeyer, S.J. (2001) MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein. Molecular and Cellular Biology, 21, 22492258.
  • Estable, M.C., Naghavi, M.H., Kato, H., Xiao, H., Qin, J., Vahlne, A. & Roeder, R.G. (2002) MCEF, the newest member of the AF4 family of transcription factors involved in leukemia, is a positive transcription elongation factor-b-associated protein. Journal of Biomedical Sciences, 9, 234245.
  • Esteller, M. (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Review, Genetics, 8, 286298.
  • Fair, K., Anderson, M., Bulanova, E., Mi, H., Tropschug, M. & Diaz, M.O. (2001) Protein interactions of the MLL PHD fingers modulate MLL target gene regulation in human cells. Molecular and Cellular Biology, 21, 35893597.
  • Fearon, E.R. & Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell, 61, 759767.
  • Felsenfeld, G. & Groudine, M. (2003) Controlling the double helix. Nature, 421, 448453.
  • Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C. & Silverman, L.R. (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncology, 10, 223232.
  • Fiskus, W., Pranpat, M., Balasis, M., Bali, P., Estrella, V., Kumaraswamy, S., Rao, R., Rocha, K., Herger, B., Lee, F., Richon, V. & Bhalla, K. (2006) Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clinical Cancer Research, 12, 58695878.
  • Garcia-Manero, G., Kantarjian, H.M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W.G., Ravandi, F., Koller, C., Xiao, L., Faderl, S., Estrov, Z., Cortes, J., O'Brien, S., Estey, E., Bueso-Ramos, C., Fiorentino, J., Jabbour, E. & Issa, J.P. (2006) Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood, 108, 32713279.
  • Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W.G., Faderl, S., Koller, C., Morris, G., Rosner, G., Loboda, A., Fantin, V.R., Randolph, S.S., Hardwick, J.S., Reilly, J.F., Chen, C., Ricker, J.L., Secrist, J.P., Richon, V.M., Frankel, S.R. & Kantarjian, H.M. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood, 111, 10601066.
  • Giles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., Kantarjian, H., Dugan, M., Albitar, M. & Bhalla, K. (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clinical Cancer Research, 12, 46284635.
  • Goodyear, O.C., Dennis, M., Jilani, N.Y., Loke, J., Siddique, S., Ryan, G., Nunnick, J., Khanum, R., Raghavan, M., Cook, M., Snowden, J.A., Griffiths, M., Russell, N., Yin, J., Crawley, C., Cook, G., Vyas, P., Moss, P., Malladi, R. & Craddock, C.F. (2012) Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood, 119, 33613369.
  • Green, A. & Beer, P. (2010) Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. The New England Journal of Medicine, 362, 369370.
  • Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A.G., Sorenson, R.J., Showalter, H.D., Murai, M.J., Belcher, A.M., Hartley, T., Hess, J.L. & Cierpicki, T. (2012) Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nature Chemical Biology, 8, 277284.
  • Gross, S., Cairns, R.A., Minden, M.D., Driggers, E.M., Bittinger, M.A., Jang, H.G., Sasaki, M., Jin, S., Schenkein, D.P., Su, S.M., Dang, L., Fantin, V.R. & Mak, T.W. (2010) Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. Journal of Experimental Medicine, 207, 339344.
  • Guenther, M.G., Jenner, R.G., Chevalier, B., Nakamura, T., Croce, C.M., Canaani, E. & Young, R.A. (2005) Global and Hox-specific roles for the MLL1 methyltransferase. Proceedings of the National Academy of Sciences of the United States of America, 102, 86038608.
  • Halby, L., Champion, C., Senamaud-Beaufort, C., Ajjan, S., Drujon, T., Rajavelu, A., Ceccaldi, A., Jurkowska, R., Lequin, O., Nelson, W.G., Guy, A., Jeltsch, A., Guianvarc'h, D., Ferroud, C. & Arimondo, P.B. (2012) Rapid synthesis of new DNMT inhibitors derivatives of procainamide. ChemBioChem, 13, 157165.
  • Hauswald, S., Duque-Afonso, J., Wagner, M.M., Schertl, F.M., Lubbert, M., Peschel, C., Keller, U. & Licht, T. (2009) Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clinical Cancer Research, 15, 37053715.
  • Heller, G., Schmidt, W.M., Ziegler, B., Holzer, S., Mullauer, L., Bilban, M., Zielinski, C.C., Drach, J. & Zochbauer-Muller, S. (2008) Genome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Research, 68, 4454.
  • Hess, J.L. (2004) MLL: a histone methyltransferase disrupted in leukemia. Trends in Molecular Medicine, 10, 500507.
  • Hoellein, A., Decker, T., Bogner, C., Oelsner, M., Hauswald, S., Peschel, C., Keller, U. & Licht, T. (2010) Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status. Journal of Cancer Research and Clinical Oncology, 136, 403410.
  • Holliday, R. (1979) A new theory of carcinogenesis. British Journal Cancer, 40, 513522.
  • Hsieh, J.J., Ernst, P., Erdjument-Bromage, H., Tempst, P. & Korsmeyer, S.J. (2003a) Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Molecular and Cellular Biology, 23, 186194.
  • Hsieh, J.J., Cheng, E.H. & Korsmeyer, S.J. (2003b) Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell, 115, 293303.
  • Huang, J., Gurung, B., Wan, B., Matkar, S., Veniaminova, N.A., Wan, K., Merchant, J.L., Hua, X. & Lei, M. (2012) The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature, 482, 542546.
  • Hyman, C.B. & Sturgeon, P. (1956) Prednisone therapy of acute lymphatic leukemia in children. Cancer, 9, 965970.
  • Issa, J.P., Garcia-Manero, G., Giles, F.J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C.S., Cortes, J. & Kantarjian, H.M. (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 103, 16351640.
  • Jain, S. & Zain, J. (2011) Romidepsin in the treatment of cutaneous T-cell lymphoma. Journal of Blood Medicine, 2, 3747.
  • Jankowska, A.M., Szpurka, H., Tiu, R.V., Makishima, H., Afable, M., Huh, J., O'Keefe, C.L., Ganetzky, R., McDevitt, M.A. & Maciejewski, J.P. (2009) Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood, 113, 64036410.
  • Jenuwein, T. & Allis, C.D. (2001) Translating the histone code. Science, 293, 10741080.
  • Jones, P.A. & Baylin, S.B. (2007) The epigenomics of cancer. Cell, 128, 683692.
  • Jurkowska, R.Z., Jurkowski, T.P. & Jeltsch, A. (2011) Structure and function of mammalian DNA methyltransferases. ChemBioChem, 12, 206222.
  • Kaminskas, E., Farrell, A., Abraham, S., Baird, A., Hsieh, L.S., Lee, S.L., Leighton, J.K., Patel, H., Rahman, A., Sridhara, R., Wang, Y.C. & Pazdur, R. (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clinical Cancer Research, 11, 36043608.
  • Kantarjian, H., Issa, J.P., Rosenfeld, C.S., Bennett, J.M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., Helmer, 3rd, R., Shen, L., Nimer, S.D., Leavitt, R., Raza, A. & Saba, H. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 106, 17941803.
  • Khare, S.P., Habib, F., Sharma, R., Gadewal, N., Gupta, S. & Galande, S. (2012) HIstome–a relational knowledgebase of human histone proteins and histone modifying enzymes. Nuclic Acids Research, 40(Database issue), D337D342.
  • Klimek, V.M., Fircanis, S., Maslak, P., Guernah, I., Baum, M., Wu, N., Panageas, K., Wright, J.J., Pandolfi, P.P. & Nimer, S.D. (2008) Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clinical Cancer Research, 14, 826832.
  • Klisovic, M.I., Maghraby, E.A., Parthun, M.R., Guimond, M., Sklenar, A.R., Whitman, S.P., Chan, K.K., Murphy, T., Anon, J., Archer, K.J., Rush, L.J., Plass, C., Grever, M.R., Byrd, J.C. & Marcucci, G. (2003) Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia, 17, 350358.
  • Klose, R.J., Kallin, E.M. & Zhang, Y. (2006) JmjC-domain-containing proteins and histone demethylation. Nature Review, Genetics, 7, 715727.
  • Ko, M., Huang, Y., Jankowska, A.M., Pape, U.J., Tahiliani, M., Bandukwala, H.S., An, J., Lamperti, E.D., Koh, K.P., Ganetzky, R., Liu, X.S., Aravind, L., Agarwal, S., Maciejewski, J.P. & Rao, A. (2010) Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature, 468, 839843.
  • Kondo, Y. (2009) Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Medical Journal, 50, 455463.
  • Kouzarides, T. (2007) Chromatin modifications and their function. Cell, 128, 693705.
  • Krivtsov, A.V. & Armstrong, S.A. (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nature Reviews, Cancer, 7, 823833.
  • Krivtsov, A.V., Feng, Z., Lemieux, M.E., Faber, J., Vempati, S., Sinha, A.U., Xia, X., Jesneck, J., Bracken, A.P., Silverman, L.B., Kutok, J.L., Kung, A.L. & Armstrong, S.A. (2008) H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell, 14, 355368.
  • Ku, M., Koche, R.P., Rheinbay, E., Mendenhall, E.M., Endoh, M., Mikkelsen, T.S., Presser, A., Nusbaum, C., Xie, X., Chi, A.S., Adli, M., Kasif, S., Ptaszek, L.M., Cowan, C.A., Lander, E.S., Koseki, H. & Bernstein, B.E. (2008) Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genetics, 4, e1000242.
  • Kuendgen, A., Knipp, S., Fox, F., Strupp, C., Hildebrandt, B., Steidl, C., Germing, U., Haas, R. & Gattermann, N. (2005) Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Annals of Hematology, 84(Suppl. 1), 6166.
  • Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., Baty, J., Welch, J., Harris, C.C., Lichti, C.F., Townsend, R.R., Fulton, R.S., Dooling, D.J., Koboldt, D.C., Schmidt, H., Zhang, Q., Osborne, J.R., Lin, L., O'Laughlin, M., McMichael, J.F., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Magrini, V.J., Vickery, T.L., Hundal, J., Cook, L.L., Conyers, J.J., Swift, G.W., Reed, J.P., Alldredge, P.A., Wylie, T., Walker, J., Kalicki, J., Watson, M.A., Heath, S., Shannon, W.D., Varghese, N., Nagarajan, R., Westervelt, P., Tomasson, M.H., Link, D.C., Graubert, T.A., DiPersio, J.F., Mardis, E.R. & Wilson, R.K. (2010) DNMT3A mutations in acute myeloid leukemia. The New England Journal of Medicine, 363, 24242433.
  • Li, H., Rauch, T., Chen, Z.X., Szabó, P.E., Riggs, A.D. & Pfeifer, G.P. (2006) The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. Journal of Biological Chemistry, 281, 1948919500.
  • Li, Z., Cai, X., Cai, C.L., Wang, J., Zhang, W., Petersen, B.E., Yang, F.C. & Xu, M. (2011) Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood, 118, 45094518.
  • Loenarz, C. & Schofield, C.J. (2008) Expanding chemical biology of 2-oxoglutarate oxygenases. Nature Chemical Biology, 4, 152156.
  • Lorsbach, R.B., Moore, J., Mathew, S., Raimondi, S.C., Mukatira, S.T. & Downing, J.R. (2003) TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia, 17, 637641.
  • Lubbert, M., Suciu, S., Baila, L., Ruter, B.H., Platzbecker, U., Giagounidis, A., Selleslag, D., Labar, B., Germing, U., Salih, H.R., Beeldens, F., Muus, P., Pfluger, K.H., Coens, C., Hagemeijer, A., Eckart Schaefer, H., Ganser, A., Aul, C., de Witte, T. & Wijermans, P.W. (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology, 29, 19871996.
  • Ma, D.K., Guo, J.U., Ming, G.L. & Song, H. (2009) DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation. Cell Cycle, 8, 15261531.
  • Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Locke, D.P., Magrini, V.J., Abbott, R.M., Vickery, T.L., Reed, J.S., Robinson, J.S., Wylie, T., Smith, S.M., Carmichael, L., Eldred, J.M., Harris, C.C., Walker, J., Peck, J.B., Du, F., Dukes, A.F., Sanderson, G.E., Brummett, A.M., Clark, E., McMichael, J.F., Meyer, R.J., Schindler, J.K., Pohl, C.S., Wallis, J.W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M.E., Ivy, J.V., Kalicki, J., Elliott, G., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., Watson, M.A., Baty, J., Heath, S., Shannon, W.D., Nagarajan, R., Link, D.C., Walter, M.J., Graubert, T.A., DiPersio, J.F., Wilson, R.K. & Ley, T.J. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. The New England Journal of Medicine, 361, 10581066.
  • Marschalek, R. (2011) Mechanisms of leukemogenesis by MLL fusion proteins. British Journal of Haematology, 152, 141154.
  • Marshall, N.F. & Price, D.H. (1995) Purification of P-TEFb, a transcription factor required for the transition into productive elongation. Journal of Biological Chemistry, 270, 1233512338.
  • Martin, C. & Zhang, Y. (2005) The diverse functions of histone lysine methylation. Nature Review, Molecular Cell Biology, 6, 838849.
  • Mazumder, A., Vesole, D.H. & Jagannath, S. (2010) Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. Clinical Lymphoma, Myeloma & Leukemia, 10, 149151.
  • Meyer, C., Schneider, B., Jakob, S., Strehl, S., Attarbaschi, A., Schnittger, S., Schoch, C., Jansen, M.W., van Dongen, J.J., den Boer, M.L., Pieters, R., Ennas, M.G., Angelucci, E., Koehl, U., Greil, J., Griesinger, F., Zur Stadt, U., Eckert, C., Szczepanski, T., Niggli, F.K., Schäfer, B.W., Kempski, H., Brady, H.J., Zuna, J., Trka, J., Lo Nigro, L., Biondi, A., Delabesse, E., Macintyre, E., Stanulla, M., Schrappe, M., Haas, O.A., Burmeister, T., Dingermann, T., Klingebiel, T. & Marschalek, R. (2006) The MLL recombinome of acute leukemias. Leukemia, 20, 777784.
  • Meyer, C., Kowarz, E., Hofmann, J., Renneville, A., Zuna, J., Trka, J., Ben Abdelali, R., Macintyre, E., De Braekeleer, E., De Braekeleer, M., Delabesse, E., de Oliveira, M.P., Cavé, H., Clappier, E., van Dongen, J.J., Balgobind, B.V., van den Heuvel-Eibrink, M.M., Beverloo, H.B., Panzer-Grümayer, R., Teigler-Schlegel, A., Harbott, J., Kjeldsen, E., Schnittger, S., Koehl, U., Gruhn, B., Heidenreich, O., Chan, L.C., Yip, S.F., Krzywinski, M., Eckert, C., Möricke, A., Schrappe, M., Alonso, C.N., Schäfer, B.W., Krauter, J., Lee, D.A., Zur Stadt, U., Te Kronnie, G., Sutton, R., Izraeli, S., Trakhtenbrot, L., Lo Nigro, L., Tsaur, G., Fechina, L., Szczepanski, T., Strehl, S., Ilencikova, D., Molkentin, M., Burmeister, T., Dingermann, T., Klingebiel, T. & Marschalek, R. (2009) New insights to the MLL recombinome of acute leukemias. Leukemia, 23, 14901499.
  • Milne, T.A., Briggs, S.D., Brock, H.W., Martin, M.E., Gibbs, D., Allis, C.D. & Hess, J.L. (2002) MLL targets SET domain methyltransferase activity to Hox gene promoters. Molecular Cell, 10, 11071117.
  • Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., Perna, F., Pandey, S., Madzo, J., Song, C., Dai, Q., He, C., Ibrahim, S., Beran, M., Zavadi, J., Nimer, S.D., Melnick, A., Godley, L.A., Aifantis, I. & Levine, R.L. (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell, 20, 1124.
  • Mosammaparast, N. & Shi, Y. (2010) Reversal of histone methylation: biochemical and molcular mechanism of histone demethylases. Annual Review of Biochemistry, 79, 155179.
  • Nakamura, T., Mori, T., Tada, S., Krajewski, W., Rozovskaia, T., Wassell, R., Dubois, G., Mazo, A., Croce, C.M. & Canaani, E. (2002) ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Molecular Cell, 10, 11191128.
  • Niehrs, C. & Schäfer, A. (2012) Active DNA demethylation by Gadd45 and DNA repair. Trends in Cell Biology, 22, 220227.
  • Nilson, I., Löchner, K., Siegler, G., Greil, J., Beck, J.D., Fey, G.H. & Marschalek, R. (1996) Exon/intron structure of the human ALL-1 (MLL) gene involved in translocations to chromosomal region 11q23 and acute leukaemias. British Journal of Haematology, 93, 966972.
  • Nilson, I., Reichel, M., Ennas, M.G., Greim, R., Knörr, C., Siegler, G., Greil, J., Fey, G.H. & Marschalek, R. (1997) Exon/intron structure of the human AF-4 gene, a member of the AF-4/LAF-4/FMR-2 gene family coding for a nuclear protein with structural alterations in acute leukaemia. British Journal of Haematology, 98, 157169.
  • Nishioka, C., Ikezoe, T., Yang, J., Udaka, K. & Yokoyama, A. (2011) Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells. Leukemia Research, 35, 932939.
  • Okabe, S., Tauchi, T., Nakajima, A., Sashida, G., Gotoh, A., Broxmeyer, H.E., Ohyashiki, J.H. & Ohyashiki, K. (2007) Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells and Development, 16, 503514.
  • Oki, Y., Kantarjian, H.M., Gharibyan, V., Jones, D., O'Brien, S., Verstovsek, S., Cortes, J., Morris, G.M., Garcia-Manero, G. & Issa, J.P. (2007) Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer, 109, 899906.
  • Ono, R., Taki, T., Taketani, T., Taniwaki, M., Kobayashi, H. & Hayashi, Y. (2002) LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Research, 62, 40754080.
  • Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.M., Gallia, G.L., Olivi, A., McLendon, R., Rasheed, B.A., Keir, S., Nikolskaya, T., Nikolsky, Y., Busam, D.A., Tekleab, H., Diaz, Jr, L.A., Hartigan, J., Smith, D.R., Strausberg, R.L., Marie, S.K., Shinjo, S.M., Yan, H., Riggins, G.J., Bigner, D.D., Karchin, R., Papadopoulos, N., Parmigiani, G., Vogelstein, B., Velculescu, V.E. & Kinzler, K.W. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 18071812.
  • Parsons, D.W., Li, M., Zhang, X., Jones, S., Leary, R.J., Lin, J.C., Boca, S.M., Carter, H., Samayoa, J., Bettegowda, C., Gallia, G.L., Jallo, G.I., Binder, Z.A., Nikolsky, Y., Hartigan, J., Smith, D.R., Gerhard, D.S., Fults, D.W., VandenBerg, S., Berger, M.S., Marie, S.K., Shinjo, S.M., Clara, C., Phillips, P.C., Minturn, J.E., Biegel, J.A., Judkins, A.R., Resnick, A.C., Storm, P.B., Curran, T., He, Y., Rasheed, B.A., Friedman, H.S., Keir, S.T., McLendon, R., Northcott, P.A., Taylor, M.D., Burger, P.C., Riggins, G.J., Karchin, R., Parmigiani, G., Bigner, D.D., Yan, H., Papadopoulos, N., Vogelstein, B., Kinzler, K.W. & Velculescu, V.E. (2011) The genetic landscape of the childhood cancer medulloblastoma. Science, 331, 435439.
  • Pless, B., Oehm, C., Knauer, S., Stauber, R.H., Dingermann, T. & Marschalek, R. (2011) The heterodimerization domains of MLL – FYRN and FYRC – are potential target structures in t(4;11) leukemia. Leukemia, 25, 663670.
  • Quintás-Cardama, A., Santos, F.P. & Garcia-Manero, G. (2011) Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia, 25, 226235.
  • Raffoux, E., Cras, A., Recher, C., Boelle, P.Y., de Labarthe, A., Turlure, P., Marolleau, J.P., Reman, O., Gardin, C., Victor, M., Maury, S., Rousselot, P., Malfuson, J.V., Maarek, O., Daniel, M.T., Fenaux, P., Degos, L., Chomienne, C., Chevret, S. & Dombret, H. (2010) Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget, 1, 3442.
  • Rambaldi, A., Dellacasa, C.M., Finazzi, G., Carobbio, A., Ferrari, M.L., Guglielmelli, P., Gattoni, E., Salmoiraghi, S., Finazzi, M.C., Di Tollo, S., D'Urzo, C., Vannucchi, A.M., Barosi, G. & Barbui, T. (2010) A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology, 150, 446455.
  • Raval, A., Tanner, S.M., Byrd, J.C., Angerman, E.B., Perko, J.D., Chen, S.S., Hackanson, B., Grever, M.R., Lucas, D.M., Matkovic, J.J., Lin, T.S., Kipps, T.J., Murray, F., Weisenburger, D., Sanger, W., Lynch, J., Watson, P., Jansen, M., Yoshinaga, Y., Rosenquist, R., de Jong, P.J., Coggill, P., Beck, S., Lynch, H., de la Chapelle, A. & Plass, C. (2007) Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell, 129, 879890.
  • Reddy, P., Maeda, Y., Hotary, K., Liu, C., Reznikov, L.L., Dinarello, C.A. & Ferrara, J.L. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proceedings of the National Academy of Sciences of the United States of America, 101, 39213926.
  • Richardson, P., Mitsiades, C., Colson, K., Reilly, E., McBride, L., Chiao, J., Sun, L., Ricker, J., Rizvi, S., Oerth, C., Atkins, B., Fearen, I., Anderson, K. & Siegel, D. (2008) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukemia & Lymphoma, 49, 502507.
  • Rozovskaia, T., Rozenblatt-Rosen, O., Sedkov, Y., Burakov, D., Yano, T., Nakamura, T., Petruck, S., Ben-Simchon, L., Croce, C.M., Mazo, A. & Canaani, E. (2000) Self-association of the SET domains of human ALL-1 and of Drosophila TRITHORAX and ASH1 proteins. Oncogene, 19, 351357.
  • Shaker, S., Bernstein, M., Momparler, L.F. & Momparler, R.L. (2003) Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leukemia Research, 27, 437444.
  • Shi, Y. & Whetstine, J.R. (2007) Dynamic regulation of histone lysine methylation by demethylases. Molecular Cell, 25, 114.
  • Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J.R., Cole, P.A., Casero, R.A. & Shi, Y. (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 119, 941953.
  • Singh, B.N., Zhang, G., Hwa, Y.L., Li, J., Dowdy, S.C. & Jiang, S.W. (2010) Nonhistone protein acetylation as cancer therapy targets. Expert Review of Anticancer Therepy, 10, 935954.
  • Slany, R.K. (2009) The molecular biology of mixed lineage leukemia. Haematologica, 94, 984993.
  • Smallwood, A., Estève, P.O., Pradhan, S. & Carey, M. (2007) Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes & Development, 21, 11691178.
  • Soriano, A.O., Yang, H., Faderl, S., Estrov, Z., Giles, F., Ravandi, F., Cortes, J., Wierda, W.G., Ouzounian, S., Quezada, A., Pierce, S., Estey, E.H., Issa, J.P., Kantarjian, H.M. & Garcia-Manero, G. (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood, 110, 23022308.
  • Spyridonidis, A., Labopin, M., Schmid, C., Volin, L., Yakoub-Agha, I., Stadler, M., Milpied, N., Socie, G., Browne, P., Lenhoff, S., Sanz, M.A., Aljurf, M., Mohty, M. & Rocha, V. (2012) Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia, 26, 12111217.
  • Stransky, N., Egloff, A.M., Tward, A.D., Kostic, A.D., Cibulskis, K., Sivachenko, A., Kryukov, G.V., Lawrence, M.S., Sougnez, C., McKenna, A., Shefler, E., Ramos, A.H., Stojanov, P., Carter, S.L., Voet, D., Cortés, M.L., Auclair, D., Berger, M.F., Saksena, G., Guiducci, C., Onofrio, R.C., Parkin, M., Romkes, M., Weissfeld, J.L., Seethala, R.R., Wang, L., Rangel-Escareño, C., Fernandez-Lopez, J.C., Hidalgo-Miranda, A., Melendez-Zajgla, J., Winckler, W., Ardlie, K., Gabriel, S.B., Meyerson, M., Lander, E.S., Getz, G., Golub, T.R., Garraway, L.A. & Grandis, J.R. (2011) The mutational landscape of head and neck squamous cell carcinoma. Science, 333, 11571160.
  • Stresemann, C. & Lyko, F. (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. International Journal of Cancer, 123, 813.
  • Tong, W.G., Wierda, W.G., Lin, E., Kuang, S.Q., Bekele, B.N., Estrov, Z., Wei, Y., Yang, H., Keating, M.J. & Garcia-Manero, G. (2010) Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics, 5, 499508.
  • Tsai, H.C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F.V., Shin, J.J., Harbom, K.M., Beaty, R., Pappou, E., Harris, J., Yen, R.W., Ahuja, N., Brock, M.V., Stearns, V., Feller-Kopman, D., Yarmus, L.B., Lin, Y.C., Welm, A.L., Issa, J.P., Minn, I., Matsui, W., Jang, Y.Y., Sharkis, S.J., Baylin, S.B. & Zahnow, C.A. (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell, 21, 430446.
  • Turner, B.M. (2000) Histone acetylation and an epigenetic code. BioEssays, 22, 836845.
  • Turner, B.M. (2002) Cellular memory and the histone code. Cell, 111, 285291.
  • Walter, M.J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Kandoth, C., Baty, J., Westervelt, P., DiPersio, J.F., Mardis, E.R., Wilson, R.K., Ley, T.J. & Graubert, T.A. (2011) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia, 25, 11531158.
  • Wang, H., Zhou, W., Zheng, Z., Zhang, P., Tu, B., He, Q. & Zhu, W.G. (2012) The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Repair (Amst.), 11, 146156.
  • Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Coller, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., Rabinowitz, J.D., Carroll, M., Su, S.M., Sharp, K.A., Levine, R.L. & Thompson, C.B. (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 17, 225234.
  • Wilhelm, M., O'Brien, S., Rios, M.B., Estey, E., Keating, M.J., Plunkett, W., Sorenson, M. & Kantarjian, H.M. (1999) Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leukemia & Lymphoma, 34, 511518.
  • Willemze, R., Suciu, S., Archimbaud, E., Muus, P., Stryckmans, P., Louwagie, E.A., Berneman, Z., Tjean, M., Wijermans, P., Döhner, H., Jehn, U., Labar, B., Jaksic, B., Dardenne, M. & Zittoun, R. (1997) A randomized phase II study on the effects of 5-Aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia, 11(Suppl. 1), S24S27.
  • Williams, S.C., Karajannis, M.A., Chiriboga, L., Golfinos, J.G., von Deimling, A. & Zagzag, D. (2011) R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1alpha upregulation in adult glioma. Acta Neuropathologica, 121, 279281.
  • Wilson, A.G. (2008) Epigenetic regulation of gene expression in the inflammatory response and relevance to common diseases. Journal of Periodontology, 79(Suppl), 15141519.
  • Wong, H.K., Mishra, A., Hake, T. & Porcu, P. (2011) Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). British Journal of Haematology, 155, 150166.
  • Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjöblom, T., Leary, R.J., Shen, D., Boca, S.M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso, Z., Ustyanksky, V., Nikolskaya, T., Nikolsky, Y., Karchin, R., Wilson, P.A., Kaminker, J.S., Zhang, Z., Croshaw, R., Willis, J., Dawson, D., Shipitsin, M., Willson, J.K., Sukumar, S., Polyak, K., Park, B.H., Pethiyagoda, C.L., Pant, P.V., Ballinger, D.G., Sparks, A.B., Hartigan, J., Smith, D.R., Suh, E., Papadopoulos, N., Buckhaults, P., Markowitz, S.D., Parmigiani, G., Kinzler, K.W., Velculescu, V.E. & Vogelstein, B. (2007) The genomic landscapes of human breast and colorectal cancers. Science, 318, 11081113.
  • Wu, H. & Zhang, Y. (2011) Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes & Development, 25, 24362452.
  • Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Wang, P., Xiao, M.T., Liu, L.X., Jiang, W.Q., Liu, J., Zhang, J.Y., Wang, B., Frye, S., Zhang, Y., Xu, Y.H., Lei, Q.Y., Guan, K.L., Zhao, S.M. & Xiong, Y. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell, 19, 1730.
  • Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J., Friedman, H., Friedman, A., Reardon, D., Herndon, J., Kinzler, K.W., Velculescu, V.E., Vogelstein, B. & Bigner, D.D. (2009) IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine, 360, 765773.
  • Yan, X.J., Xu, J., Gu, Z.H., Pan, C.M., Lu, G., Shen, Y., Shi, J.Y., Zhu, Y.M., Tang, L., Zhang, X.W., Liang, W.X., Mi, J.Q., Song, H.D., Li, K.Q., Chen, Z. & Chen, S.J. (2011) Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nature Genetics, 43, 309315.
  • Yao, Y., Chen, P., Diao, J., Cheng, G., Deng, L., Anglin, J.L., Prasad, B.V. & Song, Y. (2011) Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. Journal of the American Chemical Society, 133, 1674616749.
  • Yokoyama, A. & Cleary, M.L. (2008) Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell, 14, 3646.
  • Yokoyama, A., Kitabayashi, I., Ayton, P.M., Cleary, M.L. & Ohki, M. (2002) Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood, 100, 37103718.
  • Yokoyama, A., Wang, Z., Wysocka, J., Sanyal, M., Aufiero, D.J., Kitabayashi, I., Herr, W. & Cleary, M.L. (2004) Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Molecular and Cellular Biology, 24, 56395649.
  • Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., Ding, J., Lei, Q., Guan, K.L. & Xiong, Y. (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science, 324, 261265.
  • Ziemba, A., Hayes, E., Freeman, 3rd, B.B., Ye, T. & Pizzorno, G. (2011) Development of an oral form of azacytidine: 2′3′5′triacetyl-5-azacytidine. Chemotherapy Research and Practice, 2011, 965826.